Medical Condition News

RSS

Many abusers switch to heroin due to new formulation of OxyContin

A change in the formula of the frequently abused prescription painkiller OxyContin has many abusers switching to a drug that is potentially more dangerous, according to researchers at Washington University School of Medicine in St. Louis.

12 Jul 2012

New assay can identify rare cancerous cells within mixed populations

Rare cells can be identified within mixed cell populations with near perfect accuracy using a detection technique devised by research teams led by Robert Wieder, MD, PhD, at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School and Rajan Kumar, MD, PhD, at Genome Data Systems in Hamilton, N.J. This technique may facilitate cancer diagnosis, which often relies on the detection of rare cancerous cells in tiny amounts of biopsy tissue or fluid.

12 Jul 2012

Study details how resistance to targeted drug therapy emerges in colorectal cancers

A Harvard researcher studying the evolution of drug resistance in cancer is predicting that, in a few decades, "many, many cancers could be manageable."

12 Jul 2012

Study shows high rates of concussion among collegiate football players

As interest in concussion rates and prevention strategies at all levels continues to grow, one population that appears to have increasing head injury rates is collegiate football players.

12 Jul 2012

New book outlines cutting-edge approach to systematically address AD

ADEC Inc. - Worried about your memory? Many patients with Alzheimer's disease (AD) and individuals concerned about developing memory loss feel they have limited options. While there is no 'magic pill' to cure or prevent AD, a new book outlines a cutting-edge approach to systematically address this disease.

12 Jul 2012

Novel molecular mechanism responsible for most important symptom of major depression

Stanford University School of Medicine scientists have laid bare a novel molecular mechanism responsible for the most important symptom of major depression: anhedonia, the loss of the ability to experience pleasure.

12 Jul 2012

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

Prenatal and early childhood exposure to PCE may be associated with long-term visual impairments

Prenatal and early childhood exposure to the chemical solvent tetrachloroethylene (PCE) found in drinking water may be associated with long-term visual impairments, particularly in the area of color discrimination, a new study led by Boston University School of Public Health (BUSPH) researchers has found.

12 Jul 2012

Powerful brain chemical systems work together to paralyze skeletal muscles during REM sleep

Two powerful brain chemical systems work together to paralyze skeletal muscles during rapid eye movement (REM) sleep, according to new research in the July 11 issue of The Journal of Neuroscience. The finding may help scientists better understand and treat sleep disorders, including narcolepsy, tooth grinding, and REM sleep behavior disorder.

12 Jul 2012

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON Pharma today announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer.

12 Jul 2012

Naturally occurring molecule may prevent plaque buildup inside arteries

Cleveland Clinic researchers have discovered that a naturally occurring molecule may play a role in preventing plaque buildup inside arteries, possibly leading to new plaque-fighting drugs and improved screening of patients at risk of developing atherosclerosis.

12 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

FDA approves Watson’s ANDA for generic ARTHROTEC

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc - Florida has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium and Misoprostol Delayed-Release Tablets, the generic equivalent to G.D. Searle's ARTHROTEC.

12 Jul 2012

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Among intermediate- to high-risk patients undergoing coronary artery bypass graft surgery, administration of the agent acadesine to regulate adenosine (a naturally occurring chemical that dilates blood flow and can improve coronary blood flow and perfusion) did not reduce all-cause death, nonfatal stroke, or need for mechanical support for ventricular dysfunction, for approximately a month after surgery, according to a study in the July 11 issue of JAMA.

12 Jul 2012

Oligodendroglia cells: An interview with Jeffrey Rothstein

There are three principle cells in the brain: neurons and two types of glial cells. One type is called an astrocyte. These were well known to inactivate neurotransmitters like glutamate, and provide metabolic support to neurons.

11 Jul 2012

Research into “insulating” brain cells could help to cure neurodegenerative diseases such as ALS

Johns Hopkins researchers say they have discovered that the central nervous system's oligodendroglia cells, long believed to simply insulate nerves as they "fire" signals, are unexpectedly also vital to the survival of neurons. Damage to these insulators appears to contribute to brain injury in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease for the Yankee baseball great who died from the disease.

11 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

Physicians need to know how chemical intolerance affects people: Study

Chemical intolerance contributes to the illnesses of 1 in 5 patients but the condition seldom figures in their diagnosis, according to clinical research directed by a UT Medicine San Antonio physician.

11 Jul 2012

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BioInvent International AB today announced data from the GLACIER phase IIa study evaluating BI-204 in patients with stable atherosclerotic vascular disease. BioInvent is developing BI-204 in collaboration with Genentech, a member of the Roche Group.

11 Jul 2012

BWH performs New England's first implant of SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Harvard-affiliated Brigham and Women's Hospital in Boston has performed New England's first implant of the SynCardia temporary Total Artificial Heart.

11 Jul 2012

Medical Condition News

Many abusers switch to heroin due to new formulation of OxyContin

New assay can identify rare cancerous cells within mixed populations

Study details how resistance to targeted drug therapy emerges in colorectal cancers

Study shows high rates of concussion among collegiate football players

New book outlines cutting-edge approach to systematically address AD

Novel molecular mechanism responsible for most important symptom of major depression

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

Prenatal and early childhood exposure to PCE may be associated with long-term visual impairments

Powerful brain chemical systems work together to paralyze skeletal muscles during REM sleep

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

Naturally occurring molecule may prevent plaque buildup inside arteries

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

FDA approves Watson’s ANDA for generic ARTHROTEC

Effective therapies to reduce perioperative morbidity and mortality remain elusive

Oligodendroglia cells: An interview with Jeffrey Rothstein

Research into “insulating” brain cells could help to cure neurodegenerative diseases such as ALS

Arrowhead initiates Adipotide Phase 1 trial in obesity

Physicians need to know how chemical intolerance affects people: Study

BioInvent announces data from BI-204 phase IIa study on stable atherosclerotic vascular disease

BWH performs New England's first implant of SynCardia temporary Total Artificial Heart

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News